Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis | Annals of the Rheumatic Diseases

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Archive
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Article info

Letter

Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis

Authors

T Keersmaekers PubMed articles Google scholar articles
K Claes PubMed articles Google scholar articles
D R Kuypers PubMed articles Google scholar articles
K de Vlam PubMed articles Google scholar articles
P Verschueren PubMed articles Google scholar articles
R Westhovens PubMed articles Google scholar articles

Dr R Westhovens, Department of Rheumatology, University Hospitals KU Leuven, Herestraat 49, B-3000 Leuven, Belgium; rene.westhovens{at}uz.kuleuven.ac.be

Citation

Keersmaekers T, Claes K, Kuypers DR, et al

Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis

Annals of the Rheumatic Diseases 2009;68:759-761.

Publication history

Accepted July 26, 2008
First published April 14, 2009.

Online issue publication

October 31, 2019

Copyright information

2009 BMJ Publishing Group and European League Against Rheumatism